Expertise in
33
conditions

Dr. Nitin B. Jain

Hematology | Oncology | Hematology Oncology
2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (861.4 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
33
conditions
2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
 (861.4 mi)
OverviewInsuranceLocationsClinical Research

Overview

Nitin Jain is a Hematologist and an Oncologist in Houston, Texas. Dr. Jain is highly rated in 33 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Endoscopy.

His clinical research consists of co-authoring 441 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Hematology Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

MD Anderson
2130 W Holcombe Blvd, Life Sciences Plaza, Houston, TX 77030
Other Locations
MD Anderson
1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Enrollment Status: Recruiting
Publish Date: February 06, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Atezolizumab, Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Recruiting
Publish Date: November 27, 2024
Intervention Type: Biological
Study Drug: ADCT-602 Monoclonal Antibody
Study Phase: Phase 1/Phase 2
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Ibrutinib, Obinutuzumab
Study Phase: Phase 2
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Other
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 2
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Ibrutinib, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: September 24, 2024
Intervention Type: Drug
Study Drug: MS-553
Study Phase: Phase 1/Phase 2
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug, Biological, Other
Study Phase: Phase 2
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Nivolumab
Study Phase: Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Biological, Drug
Study Drugs: Bosutinib, Inotuzumab, Ozogamicin
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Terminated
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

441 Total Publications

Ultrasound Guided Iliopsoas Bursa Injection Technique.
Ultrasound Guided Iliopsoas Bursa Injection Technique.
Journal: American journal of physical medicine & rehabilitation
Published: February 03, 2025
Similar Doctors
Expertise in
42
conditions
Dr. Tapan M. Kadia
Hematology | Oncology | Hematology Oncology
Expertise in
42
conditions
Dr. Tapan M. Kadia
Hematology | Oncology | Hematology Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia is highly rated in 42 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Elias J. Jabbour
Expertise in
36
conditions
Dr. Elias J. Jabbour
Hematology Oncology | Hematology | Oncology
Expertise in
36
conditions
Dr. Elias J. Jabbour
Hematology Oncology | Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances

Elias Jabbour is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Jabbour is highly rated in 36 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Naval G. Daver
Expertise in
40
conditions
Dr. Naval G. Daver
Hematology Oncology | Oncology | Hematology
Expertise in
40
conditions
Dr. Naval G. Daver
Hematology Oncology | Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naval Daver is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Daver is highly rated in 40 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile